Oral HPV Infection: Current Strategies for Prevention and Therapy by Syrj&#228 et al.
Send Orders of Reprints at reprints@benthamscience.org 
5452 Current Pharmaceutical Design, 2012, 18, 5452-5469  
 
 
Oral HPV Infection: Current Strategies for Prevention and Therapy 
Stina Syrjänen
a,#
, Nicoletta Termine
b,
*
,#
, Giuseppa Capra
c
, Carlo Paderni
b
, Vera Panzarella
b
 and Giuseppina 
Campisi
b
 
a
Department of Oral Pathology, Institute of Dentistry, University of Turku, Turku, Finland; 
b
Sector of Oral Medicine “ V. Mar-
giotta”, Section of Oral Sciences, Department of Surgical and Oncological Disciplines, University of Palermo, Palermo, Italy; 
c
Sec-
tion of Virology – Department of Sciences for Health Promotion, University of Palermo, Palermo, Italy 
Abstract: Infection with High Risk (HR) Human Papillomaviruses (HPVs) is the main aetiological agent of Cervical Squamous Cell 
Carcinoma (CSCC) and also associated in a subgroup of other neoplasms, including Oropharyngeal Squamous cell Carcinoma (OPSCC). 
HPV infection, in genital as in oral mucosa, can also be subclinical or associated with benign proliferative lesions (common warts, con-
dylomas, papillomas) caused mostly by infection with Low Risk (LR)-HPVs. In the last decades, extensive research has resulted in grow-
ing knowledge on HPV biology and specifically viral life cycle, biochemical properties of viral proteins and their interaction with the 
host proteins leading to potential new targets of prophylactic or therapeutic vaccines and therapies for HPV infection. In addition, notable 
progresses have been made in the field of diagnostics to detect HPV DNA or RNA. The recent epidemiological data suggest the signifi-
cant changes in HPV endemic, due to the changes in sexual habits especially among young generations (i.e. early sexual debuts, multiple 
sexual partners, oral and anal sex); this scenario has urged on the need of adequate campaigns of primary (sexual education, vaccination 
programs) and secondary prevention (diagnostics of HPV-related diseases). Due to the growing interest on HPV infection and HPV re-
lated cancers, the authors made a narrative review of the literature on oral HPV infection and oral-genital transmission. After this, in view 
of the controversies about the strategies of therapy and prevention of HPV infection, the present review focuses on the current state of art 
about the available tools for the therapeutic and, if any, preventive management of oral HPV infection.  
Keywords: Human papillomavirus, oral mucosa, oral diseases HPV-related, viral transmission, oral surgery, HPV vaccines, genital HPV 
infection, oral sex, head and neck cancer. 
1. INTRODUCTION  
 Human Papillomavirus (HPV) infection has been recognized as 
a necessary cause of cervical squamous cell carcinoma (CSCC) 
worldwide [1-3]. There is also strong evidence of its causal role for 
a subset of SCC, in the anogenital area (i.e. vulva, vagina, anus and 
penis) and in the head-neck districts (i.e. pharynx, larynx, oral cav-
ity). Genital HPV infection is one of the most frequent sexually 
transmitted disease, being reported with a prevalence of about 42% 
among 19-54 aged females in the US [4] and being strongly corre-
lated to sexual behavioural risk factors [5]. Moreover, epidemiol-
ogical data from last decades suggest significant changes in HPV 
endemic, with regard not only to genital but also oral area. This has 
been explained by risky sexual behaviour especially among young 
generations [6, 7]. This also would explain the increased incidence 
of HPV-related SCC in head and neck region [8-10]. Although the 
modes of HPV transmission in oral cavity (see below, paragraph 
2.a) are still not completely elucidated, epidemiological data sug-
gest that detection of HPV (i.e. HPV 16) in oral exfoliated cells 
increased the risk more than 14-fold (OR 14.6; 95% CI: 6.3-36.6) 
of oropharyngeal cancer (tonsils and base of tongue) [11] and 3.8-
fold the risk of oral cancer [12]. 
 HPV-related diseases in humans have taken an increased impor-
tance over the years and are now a major concern for public health. 
The current evidence suggests that the potential fallouts of the so 
called “HPV endemic” on the epidemiologic, therapeutic/preventive 
and socio-economic viewpoints are enormous, and in the future 
there is a great opportunity to design adequate strategies of preven-
tion and management of HPV-related diseases, including SCCs of 
anogenital and head-neck region, similarly to other infectious  
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diseases, although the medical and especially dental community, is 
probably still not acquainted with these perspectives. 
 This review focuses on oral HPV infection and oral-genital 
transmission and current state of art about the therapeutic and, if 
any, preventive management of oral HPV infection.  
2. VIROLOGY AND NATURAL HISTORY OF HPV INFEC-
TION 
2.1. HPV Genome and Source of Infection 
 HPV are small, double-stranded DNA viruses with around -
8000 base pairs, covered by an iso-exahedric capsid without enve-
lope consisting of 72 capsomeres [13-15]. Capsid proteins are rep-
resented by a major capsid protein (L1) and a minor capsid protein 
(L2). HPV genome consists of ten Open Reading Frames (ORFs) 
sequences, with potential of transcription for specific mRNA found 
in the same DNA strand. The HPV genome can be divided into 
three different regions: the first region (Early or “E” region) ex-
tends for about 45% of the viral genome and codifies for 8 early-
functional proteins (E1 - E8); the second one (Late or “L” region) 
extends for about 40% of the viral DNA and codifies for 2 late-
structural proteins (L1 and L2); the third one (Long Control Region 
or “LCR” or Upstream Regulatory Region “URR”), containing 
sequences regulating gene transcription, performs exclusively regu-
latory functions [16-18]. After HPV inoculation, the life cycle of 
HPV, the synthesis of viral DNA and the expression of viral genes 
are linked to the differentiation program of the infected epithelial 
host cells, with production of mature virion particles restricted to 
differentiated superficial cells [19]. The normal viral replication 
cycle is a highly regulated process. Thus, the dynamic of changes in 
keratinocytes, from the basal layer up to the surface, predisposes to 
the creation of a suitable micro-environment for the productive cell 
replication, responsible for the transformation of the epithelial cell 
into a permissive cell [19, 20].  
 Infection usually occurs through micro-wounds of the epithe-
lium that expose basal and para-basal cells of the squamous epithe-
lium to viral access. This process it seems coordinated by specific 
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HPV receptors, including -6 integrin, extracellular laminin 5 and 
heparan sulphate proteoglycans. After entry, HPV establishes itself 
in the cellular nucleus as episomes with a low, non-productive viral 
replication (vegetative replication) [18]. In the basal cells HPV 
replicates together with cellular DNA during S-phase at relative low 
copy numbers (20-100 copies). This initial phase, responsible for 
the latent status of infection is characterized by ORFs E1 and E2 
expression only, codifying for replication factors. In intermediate 
layer during differentiation the vegetative replication occurs and 
more than 1000 copies/cell are amplified in each cell. The episomal 
form is a kind of reservoir of infected cells, morphologically un-
distinguishable from non-infected ones; the classic viral cytopathic 
effects (acanthosis, diskeratosis, multinucleation of keratinocytes 
and coilocytosis) appear when the viral replication enters into a 
productive phase. It is characterized by the complete viral DNA 
codification and the assemblage of several infecting virions. Par-
ticularly, following the epithelial squamous differentiation, starting 
from basal and para-basal cells, where early portions of the viral 
genome are more active and going up to higher epithelial layers 
(both the intermediate and the superficial) along with the formation 
of the complete virions (i.e. the infecting viral particles) [19]. The 
virus is expelled from the epithelial cells when they undergo des-
quamation and is transmitted by direct contact (especially in pres-
ence of lesions, i.e. genital warts) or by indirect contact. 
 The genital HPV infection is classified as a Sexually Transmit-
ted Disease (STD): the transmission of the virus in the genital area 
is mostly due to sexual contact with an infected partner and the 
probability of infection is directly related with a sexual risk behav-
iour (e.g. early sexual debut, high number of partners) [21, 22]. 
Conversely, the transmission modes of oral HPV infection, the risk 
factors as well as the natural history is poorly studied. Sexual 
transmission is by far the most common route of spreading the vi-
rus. However, detection of HPV in virgins, infants and children 
suggest that vertical transmission also exists, but the exact rates and 
routes have not been well established [23-29]. Possible non-sexual 
transmission modes include vertical or horizontal transmission and 
auto-inoculation. Vertical transmission can be divided into three 
categories, according to the assumed time of HPV transmission: 1) 
peri-conceptual transmission (time around fertilization), 2) pre-natal 
(during pregnancy), and 3) peri-natal (during birth and immediately 
thereafter). Controversial views have been presented on oral sex as 
a main transmission mode of HPV [24, 30]. In the more recent Fin-
nish Family HPV Study on HPV dynamics within family, 11% and 
26% of the women and their husbands reported regular practice of 
oral sex, respectively [24, 25]. However, any significant association 
between oral sex and carriage of HPV in the oral mucosa was estab-
lished [25]. This is contradictory to the data reported by D’Souza 
and co-workers, who studied in a case-control setting, whether sex-
ual behaviour that increased the odds of oropharyngeal cancer 
would similarly increase the risk of oral HPV infections among 
their control patients [30]. HPV infection was detected in 4.8% of 
332 control patients (from an outpatient clinic) and in 2.9% of 210 
college-aged men. Among control patients, the odds of HPV-
infection developing independently increased with increased life-
time number of oral (P=0.007) or vaginal sex partners (P=0.003). 
Among college-aged men, there was an association between oral 
HPV and deep kisses (P=0.023, for trend) and oral sex (P=0.046, 
for trend) [24]. The importance of sexual transmission is confused 
by the fact that the HPV-type concordance in oral and genital infec-
tions seems to be poor between the sexual couples and even in the 
same person [26, 31-33]. 
2.2. Natural History of HPV Infection 
 The current knowledge about the natural history of oral HPV 
infection come from gynaecological literature about cervical infec-
tion, although, as recently suggested by D’Souza et al [34], oral and 
genital HPV infection seem to differ themselves about some as-
pects.  
 Regarding the natural history of cervical HPV infection, it 
would depend on the genotype involved. HPVs are traditionally 
distinguished, on the base of specific epithelial tropism, in cutane-
ous and mucosal types: the firsts infect hands and feet skin, the 
second prefer mucosal surface of upper aero-digestive tract, ano-
genital district, urethra and conjunctive [35-38]. On the basis of 
epidemiologic data regarding the behaviour of the viral lesions, 
HPV have been also divided in two groups: those at “high risk” 
oncogenic [High Risk (HR) –HPV genotypes like 16-18-31-33-35, 
39,45,51,52,53, 56,58,59, 66, 67,70,73,68, 82), associated with 
potentially and overtly malignant lesions (anogenital cancers, giant 
condyloma of Bruschke and Lowenstein) and those at “low risk” 
oncogenic [Low Risk (LR)–HPV genotypes like 2, 4, 27 (the skin 
types) and mucosal types 6, 11, 13, 32, 42), more commonly asso-
ciated with benign diseases (ordinary wart, condyloma, focal 
epithelial hyperplasia, squamous cells papilloma, Bowen’s papillo-
matosis) [39-43]. After entry to host cell, HPV infection can mani-
fest in two clinical states:  
1) subclinical or unapparent infection, that is the silent presence 
of viral genome into inoculation site without any clinical 
and/or histological and/or cytological alterations of cervical 
mucosa [44];  
2) clinical infection, expression of proliferation of infected 
keratinocytes and associated with clinical and histological le-
sions of cervical mucosa. These lesions are usually benignant 
(e.g. genital condylomas or warts) when infection is sustained 
by LR HPV [45]; conversely the HR HPV infection, especially 
when it persists for over 18-24 months [46] and it is accompa-
nied by the viral DNA integration into the eucariotic DNA in 
basal cells, may be associated with the development of poten-
tially malignant and malignant epithelial lesions of the cervical 
mucosa. The latter form of infection has been recognized as 
the necessary but not sufficient cause of cervical SCC [46, 47].  
 This biological and aetio-pathogenetical model related to cervi-
cal HPV infection has been shifted to oral infection, although with 
some important differences derived from very recent researches, 
discussed below.  
 Immune response plays a very important role in HPV infection; 
it is well documented, for instance, that in immunocompetent sub-
jects skin warts often regress spontaneously, whereas immune defi-
ciency, both inherited (e.g. warts-like epidermal dysplasia) and 
acquired (e.g. transplants, AIDS), may favour a higher incidence 
and persistence of skin and mucosal infections induced by HPV 
[48]. Nevertheless, in HPV-related diseases, immune responses are 
generally poorly expressed compared to other viral infections, since 
the viral replication cycle takes place inside maturing keratinocytes 
able to continuously remove mature virions. These viruses also 
cause cell proliferation, rather than cell lysis; as a result, during 
infection, the local or systemic viral antigens presentation to the 
immune system by the APC is minimal and infection generally 
persists for months or even years [49]. 
3. CLINIC OF HPV INFECTION 
3.1. Genital HPV Infection 
 It is believed that genital HPV infection could result in two 
different conditions, depending largely on the genotypes involved 
(Table 1). 
Genital Normal Mucosa and HPV Infection 
 HPV detection in healthy genital mucosa is a common condi-
tion characterized by staying silent of the viral genoma in the site of 
inoculation and, therefore, without any clinical, colposcopic, cyto-
logical and histological resultants. The infection can be discovered 
only with the detection of HPV-DNA in the epithelial cells, by 
means of techniques of hybridization on cytological or histological 
samples taken from healthy subjects.  
5454    Current Pharmaceutical Design, 2012, Vol. 18, No. 34 Syrjänen et al. 
 Subclinical infection can be further distinguished in productive, 
when it is accompanied by the expression of viral DNA and by the 
release of mature viral particles, and latent/persistent, when the 
virus persists, for a variable time, as episome, in the deep layers 
epithelium in a completely silent condition. Persistent HPV infec-
tion supported by HR is seen as a necessary, but not sufficient, state 
for the occurrence of cervical cancer [46]. It is estimated that a wide 
range of healthy and sexually active female population is a carrier 
of subclinical genital infection, contributing to the spread of the 
virus. The prevalence of infection among worldwide population of 
healthy women was estimated to be between 2% and 44% in rela-
tion to the sensitivity of the diagnostic test applied [44, 47, 50-52]. 
The highest prevalence (about 40%) of HPV infection was found 
among women under the age of 25 years, progressively reduced in 
successive age groups [53]. These data support the hypothesis that 
the virus, acquired after the onset of sexual activity, leading to tran-
sient infection, is eliminated in about 6-20 months [53, 54]. This 
time of clearance seem to be longer only for HPV-16 infection [18, 
22, 55, 56]. The genotypes isolated more frequently, both in pa-
tients with cervical carcinoma and in healthy controls, are 16, 18, 
45, 31 and 58; it is also common the detection of infection with 
multiple genotypes, with percentages prevalence in the two groups 
of 8, 1% and 13.9% respectively [55]. 
 In a very recent investigation on HPV infection in U.S. female, 
Hariri and colleagues, show a prevalence estimate for HPV equal to 
42.5% [4]. This percentage drops dramatically (8.8%) if the geno-
types considered are only those at high risk (HR 16 and 18), with 
higher prevalence among women aged 20-24 years [5]. 
 However, as renowned by Sanders et colleagues, most of these 
cross-sectional estimates of HPV prevalence fail to connect the 
HPV status with a chronic infection and its role in malignant trans-
formation of healthy mucosa. A longitudinal design is needed for 
all future research aimed to investigate the causal link between 
HPV infection and its oncogenic potential [6]. 
Genital Benign Lesions HPV-related 
 The most frequent clinical expression of infection is the condy-
loma acuminatum, macroscopically characterized by small, sessile 
or pedunculated multiple growths, generally asymptomatic, covered 
with keratinized epithelium, tending to confluence and to growth 
like a “cauliflower”. It is the most common sexual transmitted viral 
infection (although it can also be acquired by vertical transmission 
or extragenital contact) associated in 95% of cases with infection by 
LR-HPV 6 and 11 [22, 45, 57]. The lesion, expression of a benign 
polyclonal proliferation of infected keratinocytes, may regress 
spontaneously in 3-4 months, may remain stable or undergo an 
expansion.  
 Genital warts represent another common disease related to the 
productive infection of HPV, especially that supported by LR-HPV 
6 or 11. Diagnosis of genital warts can be confirmed by biopsy, 
although biopsy is needed only under certain circumstances (e.g., if 
the diagnosis is uncertain; the lesions do not respond to standard 
therapy; the disease worsens during therapy; the patient is immune-
compromised; or warts are pigmented, indurated, fixed, and ulcer-
ated). No data support the use of type-specific HPV nucleic acid 
tests in the routine diagnosis or management of visible genital 
warts. 
 In addition to the external genitalia (i.e., the penis, vulva, scro-
tum, perineum, and perianal skin), genital warts can occur on the 
uterine cervix and in the vagina, urethra, anus, and mouth; these 
warts are sometimes symptomatic. Depending on the size and anat-
omic location, genital warts can be painful, friable, and pruritic, 
although they are commonly asymptomatic. 
 HPV types 16, 18, 31, 33, and 35 are found occasionally in 
visible genital warts and have been associated with external genital 
(i.e., vulvar, penile, and anal). Patients who have visible genital 
warts can be infected simultaneously with multiple HPV types [5, 
58]. 
Genital Potentially/Overtly Malignant Lesions HPV-related 
 HPV persistent infection, supported by HR genotypes, is con-
sidered a necessary condition and an important cause for the occur-
rence of cervical and anogenital (such as vaginal, vulvar, penile and 
anal) potentially/overtly malignant lesions respectively [59]. Due to 
the close connection between HPV infection and cervical cancer, 
the discussion will focus on that district.  
 Cervical potentially malignant lesions are defined as circum-
scribed areas of the mucosal lining of the cervix characterized by 
varying degrees of epithelial dysplasia, burdened by a greater neo-
plastic potential than the normal mucosa. Over 90% of these condi-
tions are HPV-positive; in some cases, the genome is only present 
in episomic or integrated form, in other cases, the complete virions 
are visible by electronic microscope [45, 60-64].  
 From histological point of view, dysplastic lesions usually have 
an uneven surface, sharp edges, non-uniform caliber of vessels, 
after application of acetic acid often assume pearly white bulleted 
or "mosaic" and are iodine-negative at test of Schiller.  
 According to the Bethesda classification, there are three catego-
ries of cytological findings concerning these cervical lesions:  
I. ASC (Atypical Squamous Cells), further divided into: 
I.a ASC-US (Atypical Squamous Cells of Undetermined 
Significance);  
I.b ASC-H (Atypical Squamous Cells, cannot exclude H-
SIL);  
II. L-SIL (Low-grade Squamous Intraepithelial Lesion); 
III. H-SIL (High-grade Squamous Intraepithelial Lesion); 
IV. Carcinoma. 
 Currently, researchers are apt to believe that the lesions referred 
to as L-SIL and H-SIL are the expression of two distinct pathoge-
netic processes, both induced by HPV. The genotypes more de-
tected are the HR, except for a portion of L-SIL, about 30%, result-
ing LR-HPV- positive [22, 60]. The L-SILs represent the transient 
Table1. Conditions Potentially Associated with HPV Infection in Genital/Cervical Mucosa 
TAB.1 CERVICAL/GENITAL HPV INFECTION 
SUB-CLINICAL CLINICAL 
BENIGN LESIONS 
POTENTIALLY/OVERTLY MALIGNANT 
DISORDERS 
Normal mucosa 
Condyloma acuminatus 
Warts (Verruca vulgaris) 
CIN, VaIN, VuIN, AIN, PIN 
SCC of uterine cervix, vagina, vulva, anus, penis 
CIN: Cervical Intraepithelial Neoplasia; VaIN: Vaginal Intraepithelial Neoplasia; VuIN: Vulvar Intraepithelial Neoplasia; AIN: Anal Intraepithelial Neoplasia; PIN: Penis Intraepi-
thelial Neoplasia. 
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expression of viral production, and are not accompanied by disrup-
tion of differentiation and maturation processes of epithelium. The 
H-SILs, however, are considered the true precursors of cervical 
cancer. These lesions are the result of HPV infection in metaplastic 
and immature cells, resulting in disruption of the differentiation 
process of epithelium, in the uncontrolled replication of cells and in 
the accumulation of genetic abnormalities, to the selection of a 
clone of cancer cells [22]. The mean age of H-SIL onset is 28 years; 
compared with the average ages of acquisition of HPV infection 
(20-25 years) and of onset of cervical cancer (40-50 years), we 
deduce some key points: the interval of time during which the virus 
is able to induce dysplastic changes is relatively short, while the 
time needed within these alterations develop invasive cancer is 
about two decades. 
 This suggests a very long time to tumor progression, during 
which a variety of factors, in addition to HPV, play a role in pro-
moting the malignant progression. 
 Cervical carcinoma represents the second cause of death among 
women worldwide after breast cancer. The curve of incidence of 
this tumor shows a gradual increase to over 55 years, with a peak 
around 48 years [1, 22, 37, 65, 66]. The association between genital 
HPV infection and cervical cancer, suggested in the 80s by Harold 
zur Hausen [67] has been widely confirmed by numerous epidemi-
ological and molecular studies carried out in the last decades. The 
DNA of HPV 16, 18 and 33 has been shown in over 90% of inva-
sive cervical carcinomas [1, 68-71]. The information obtained in the 
last years on the replication cycle of the virus and its interaction 
with the transitional epithelium of the cervix, have allowed the 
development of a pathogenetic model of cervical cancer consists of 
three basic stages:  
i)   persistent HR HPV;  
ii) progression of HVP-related epithelial dysplasia (from mild  
     to severe degree);  
iii) local tumor invasion and distant spread. 
 The reason why a small percentage of infections tends to persis-
tence and neoplastic evolution is still debated and, according to the 
most recent and accredited acquisitions, is to search in the inter-
individual differences in HLA (Human Histhocompatibilty Leuko-
cyte Antigen) haplotype [46]. 
3.2. Oral HPV Infection 
 The natural history of viral infection in the oral cavity is not 
clear, though having characteristics in common with those de-
scribed for the cervical district. In the oral cavity, HPVs have been 
detected both in healthy oral mucosa and in several lesions, as re-
ported on Table 2. 
Normal Oral Mucosa and HPV Infection 
 The detection rate of asymptomatic oral HPV infection in adults 
(i.e. presence of HPV DNA) varies among different studies from 
0% to 81%. The mean prevalence rate is approximately 11% [6, 7, 
72-81]. Kreimer and co-workers made a new meta-analysis on HPV 
detection in oral mucosa and showed that only 4.5% (95% CI: 3.9-
5.1) of 4070 subjects were positive for any HPV and 3.5% (95% 
CI: 3.0-4.1) of 4441 subjects had carcinogenic mucosal HPV [59]. 
HPV16 was detected in 1.3% (95% CI: 1.0-1.7%) of 3977 healthy 
subjects accounting 28% of all HPV positive cases of the oral re-
gion [82]. Detection rate of any HPV varied widely in individual 
studies from 2.6% to 20.7%, even when the same PCR primers 
were used [59]. The reasons for this variability would be found in 
the lack of standardization of the parameters used in the several 
investigations such as: samples size characteristics of ethno-
geographic and socio-demographic variables of the populations 
examined, the nature of the specimens (histology vs. cytology), 
sensitivity of the diagnostic test used for the viral detection (ie, 
SBH, DBH, ISH, PCR and nested variant) and inclusion criteria for 
mucosal lesions based on different classification systems [59, 79]. 
The most recent systematic review of the literature on this topic 
selected 18 studies investigating HVP-DNA prevalence in 4581 
cancer-free subjects which resulted in a 4.5% and 3.5% overall 
prevalence of any HPV and HR-HPV only, respectively [82]. These 
results are similar to those reported in a previous systematic review 
regarding HPV infection in OSCC and potentially malignant disor-
ders [12] that registered, among control samples from healthy oral 
mucosa, percentages of HPV infection equal to 12%. Based on 
these results, it is believed that the oral mucosa represents a reser-
voir of infection, excluding a primary involvement of the virus in 
the process of oral carcinogenesis. 
Oral Benign Lesions HPV-related 
 HPV has involved in a variety of benign oral lesion such as 
common wart (verruca) (Fig. 1 and 2), condyloma acuminatum 
(Fig. 3), squamous cell papilloma (SCP) (Fig. 4 and 5) and focal 
epithelial hyperplasia (FEH) (Fig. 6). These are asymptomatic exo-
phytic growths, single or multiple, with surface smooth or warty, 
white or pinkish depending on the degree of epithelial keratiniza-
tion; from the histological point of view are characterized by 
epithelial polyclonal proliferation, koilocytosis and dyskeratosis 
[83-85]. The lesion may affect any part of the oral surface, more 
frequently on the tongue, the soft palate and the lips. These lesions  
Table 2. Conditions Potentially Associated with HPV Infection in Oral Cavity 
TAB. 2 ORAL/OROPHARYNGEAL HPV INFECTION 
SUB-CLINICAL CLINICAL 
BENIGN LESIONS 
POTENTIALLY/OVERTLY MALIGNANT 
DISORDES 
Normal mucosa 
 
Squamous cell papilloma 
 
Condyloma acuminatum 
 
Wart (verruca vulgaris) 
 
Focal epithelia hyperplasia 
Oral potentially malignant disorders  (OL, PVL, 
OLP) 
 
OSCC, VC, OPSCC 
OL: Oral Leukoplakia;PVL: Proliferative Verrucous Leukoplakia; OLP: Oral Lichen Planus; OSCC: Oral Squamous Cell Carcinoma, VC: Verrucous Carcinoma, OPSCC: Oro-
pharyngeal Squamous Cell Carcinoma 
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Fig. (1). Oral wart of the hard palate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Oral wart of the dorsal surface of the  tongue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Condyloma acuminate of the palate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Oral squamous cell papilloma (SCP) of the palate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Oral SCP of the tongue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Focal Epithelial Hyperplasia (FEH) of the hard and soft palate. 
 
are in most cases clinically indistinguishable and their differential 
diagnosis is based on histopathology. Condyloma acuminatum is 
characterized by a central core connective tissue in a treelike struc-
ture covered with epithelium presenting acanthosis (ie hyperplasia 
of the spinous layer), koilocytosis (ie presence of cells with pykno-
tic and irregularly shaped nuclei surrounded by a perinuclear vacuo-
lation), parakeratosis (i.e. abnormal formation of horn cells of the 
not keratinized epithelium caused by the persistence of nuclei, in-
complete formation of keratin, and moistness and swelling of the 
horn cells) associated with the presence of chronic inflammatory 
infiltrate in the dermis. Oral SCPs are a small benign growth that 
begins in squamous epithelial cells. The lesion appears as a soft, 
pedunculated mass with numerous finger-like projections. The pro-
jections may be long and pointy or short and rounded if keratin 
(skin-forming protein) has built-up round the lesion. Less kerati-
nized lesions are pink or red in color and resemble a raspberry, 
whilst heavily keratinized lesions are white and look like the head 
of a cauliflower. The covering squamous epithelium shows a nor-
mal maturation pattern, although occasional papillomas demon-
strate pronounced basilar hyperplasia and mild mitotic activity 
which could be mistaken for mild epithelial dysplasia may or may 
not be found in the superficial layers of the epithelium. The SCP 
differs from the oral condyloma acuminatum in that its surface 
projections are typically more elongated and more often pointed. It 
will usually have considerably more keratin on its surface and is 
much less likely to contain koilocytes in large numbers. The ver-
ruca vulgaris is also characterized by a proliferation of hyperkera-
totic stratified squamous epithelium arranged into finger-like or 
pointed projections, each with its connective tissue core. It differs 
from SCP in that elongated rete ridges tend to converge toward the 
center of the lesion, producing a "cupping" effect. Also, a promi-
nent granular cell layer (hypergranulosis) exhibiting coarse, 
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clumped keratohyaline granules is typically found and abundant 
koilocytes are often seen in the superficial spinous layer. Eosino-
philic intranuclear viral inclusions are sometimes noted within the 
cells of the granular layer, a feature never found in the SCP. The 
HPV-related etiology of these lesions is suggested by the presence 
of LR HPV DNA, such as HPV -2, HPV-4 and HPV-57 (warts), 
HPV-6 and HPV-11 (SCPs and condylomas), HPV-32 and HPV-13 
(FEH), in more than 80% of cases [28]. 
 There are no population-based studies on the incidence or 
prevalence of oral papillomas or condylomas. The largest cohort 
comprises 20.000 Swedish citizens, of whom 0.1% had oral warty 
lesions [86]. 
 SCPs are the most common benign tumors of oral epithelium. 
However, in some text books, papillomas are clumped together with 
benign epithelial neoplasia, which represent a reaction to injury 
rather than true tumors. SCPs are reported to be most frequent in 
children and adults in their 4th and 5th decades. There are also 
some rare syndromes which are known to be associated with multi-
ple oral papillomas, e.g. focal dermal hypoplasia syndrome, ac-
rodermatitis enteropatica, Cowdens´s syndrome, nevus unius later-
alis, Costello syndrome and Down syndromes (OMIM data base, 
http: //www.ncbi.nlm.nih.gov/omim OMIM). 
 Oral condylomas have been traditionally associated with oral 
sex, in contrast to oral SCP. However, no reliable differential diag-
nostics can be done between oral SCP and oral condyloma on the 
basis of this socio-behavioural variable. In the literature published 
by 1998, the author found a total of 481 SCPs and 284 OCs, of 
which 50% and 75% tested HPV-positive. HPV6 and 11 were the 
major HPV types in these lesions [43, 81, 87-90]. 
 The role of HPV in other benign epithelial hyperplasia is un-
known. Recently some evidence was presented that the majority of 
white oral patches’ containing hyperplasia but not dysplasia harbor 
low copies of HR HPV DNA [91]. 
Oral Potentially Malignant/Overtly Disorders HPV-related 
 HPV prevalence, in oral potentially malignant disorders 
(OPMD) and in oral squamous cell carcinoma (OSCC) ranges from 
0% to 85% [43] with a higher prevalence of HPV 16 or 18 geno-
types [92-96]. Such a wide variation is probably due to: i) demo-
graphic variables, ii) different categorization of lesions investigated 
(sometimes not supported by histology) and different site of the 
mucosa examined, iii) different sampling techniques (biopsies, 
mouth rinsing or brushing) and different detection techniques - 
from the less sensitive ISH to the highly sensitive “nested” PCR 
[43]. 
 To date, data on HPV prevalence in Oral Leukoplakia (OL) 
(Fig. 7) are still controversial. Miller and White [77], in a review of 
studies using ISH to identify HPV in benign OL (i.e. without dys-
plasia), reported a prevalence ranging from 0% to 80%, signifi-
cantly greater in fresh and frozen specimens (43.1%) than in paraf-
fin-embedded tissues (12.2%). However, in OL with dysplasia and 
using PCR for HPV-DNA detection, the prevalence ranged from 
17% [97] up to 68.6% [72]. Moreover, if Uppsala criteria are con-
sidered [98] and the Proliferative Verrucous Leucoplakia (PVL) is 
excluded from the analysis, the overall HPV prevalence in other OL 
dropped to 17.6% (in paraffin-embedded biopsies from non-
dysplastic and dysplastic lesions) [99].  
 Campisi et al examined the relationship in OL between HPV 
and some molecular predictors of malignant progression such as 
apoptosis markers (bcl-2 and survivin) and proliferation markers 
(Proliferating Cell Nuclear Antigen; PCNA). The risk of HR-HPV 
infection was found to be independently associated with survivin 
and PCNA expression, suggesting that these markers could be in-
volved in HPV-mediated disorders of epithelial maturation [100]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Oral Leukoplakia (OL) - non homogeneous form - of the buccal 
mucosa. 
 
 Recently, Szarka et al reported an increase of HPV prevalence 
in OPMD with increasing malignant potential: 32.8%, 40.9% and 
47.7% in Oral Lichen Planus, OL and OSCC respectively [101]. 
 Oral proliferative verrucous leukoplakia (OPVL) (Fig. 8) is a 
different and particularly aggressive form of OL that, in the past, 
seemed to have the strongest relationship to HPV infection. After, 
the association of OPVL and HPV (especially genotype 16) has 
been supported by several reports [96, 102, 103], although with a 
wide range from 10% to 85%, of HPV infection [96, 102]. How-
ever, a multi-centre study recently reported no statistically signifi-
cant difference, in terms of HPV-DNA detection, between OPVL 
(24.1%) and common OL (25.5%) - nor any special role for HPV in 
PVL onset [104]. To date, this controversy remains not to be re-
solved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Oral Proliferative Verrucous Leukoplakia (PVL) of the buccal and 
masticatory mucosa. 
 
 Oral erythroplakia (OE) (Fig. 9) is a potentially malignant dis-
order with the highest potential for malignant transformation. It is 
described as a “red patch clinically and pathologically un-related to 
any other disease” [105]. By 1998, only 11 OEs have been screened 
for HPV DNA and 54.5% has tested HPV 16 positive [12]. 
 Oral Lichen Planus (OLP) (Fig. 10) is a chronic inflammatory 
disease of unknown aetiology and immune pathogenesis, with a 
small malignant potential. Information on HPV infection in OLP is 
scanty, but the few studies published report a high frequency [106, 
107] from 27.3% (75), to 42.0% [108] or even 65.0% [109]. Both 
Gonzales-Moles [110] and Jontell [109] observed that only the 
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Fig. (9). Oral eritroplakia of the border of the tongue. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10). Oral Lichen Planus - reticular form- of the tongue. 
 
erosive variant of OLP was found to be HPV positive but this was 
not confirmed in another study [111]. In the recent systematic re-
view of HPV and OPMDs, the prevalence of any HPV genotypes 
and only HPV-16 in OLP were 5.12% and 5.61 respectively [12]. 
 With almost 130,000 annual deaths worldwide, OSCC (Fig. 11 
and 12) is considered a public health emergency [112]. Usually 
OSCC is characterized by a very aggressive behaviour and a poor 
prognosis, with an overall 5 years survival rate of 59.4%, [9, 113]. 
Recently, HR HPV genotypes have been identified as etiologic 
agents for a subset of SCCs of oral cavity and oropharynx, espe-
cially in non-smoker and non-drinker subjects [114, 115]. The hy-
pothesis of the participation of HPV in oral and oropharyngeal car-
cinogenesis was first proposed by Syrjanen et al [116] and then 
supported by several other authors [38, 65, 117-121] on the basis of 
the following evidence: a) the epitheliotropic nature of HPV; b) the 
widely confirmed oncogenic potential of HR gt in the pathogenesis 
of anogenital neoplasms; and c) the morphological similarities be-
tween oropharyngeal and genital epithelia [122].  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (11). Oral Squamous Cell Carcinoma (OSCC) of the tongue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (12). OSCC of the alveolar ridge. 
 
 Nevertheless, the role of HPV infection in oral carcinogenesis is 
still unclear because conflicting results have been reported. A very 
wide range of viral prevalence (0%-100%), in addition to the pres-
ence of HR HPV in normal oral mucosa, has been reported in litera-
ture [43, 73, 77]. Apart from the differences among the patient 
groups examined regarding ethno-geographical characteristics and 
sexual behaviour, this wide range of prevalence could be related to: 
i) the site of lesion (oral cavity vs. oropharynx and tonsils), and ii) 
the sensitivity of the applied diagnostic technique, in terms of sam-
pling method and HPV detection procedure.  
 The last comprehensive meta-analysis conducted on this issue 
(and utilizing a strict case-control setting) showed that HPV signifi-
cantly increase the risk for OSCC, as compared with the controls 
(OR 3.98, 95% CI: 2.62-6.02); especially when HPV 16 is investi-
gated (pooled OR 3.86, 95% CI: 2.16-6.87) [12]. However, the 
HPV association was found to be significant also when biopsy 
samples of OSCC were compared with cytological samples of the 
controls. According to this findings and considering that that HPV 
infection is multi-focal (but not necessarily persistent/oncogenic), 
the authors recommend the use of biopsied tissue for HPV testing in 
future studies [12]. 
3.3. Oro-genital HPV Infection  
 Few published investigations have evaluated how frequently 
HPV infection occurs simultaneously in the oral districts and in the 
female genital area. Research so far has tried to clarify the nature of 
this correlation by studying social-behavioural risk factors and in 
particular, transference of the virus to different epithelial sites in the 
same patient. With regard to this aspect, various authors consider 
the two most common transmission patterns of HPV from one anat-
omic site to another, as being sexual transmission through oral-
genital contact with an infected partner and self-inoculation. In 
order to study how infection is transmitted, various researchers 
have used questionnaires designed to assess the impact of factors 
likely to cause genital infection, such as, early sexual exposure, a 
high number of partners in general and in the last year, number of 
pregnancies, level of education, contraceptive methods, sexual hab-
its and also personal hygiene standards of the patients. On examin-
ing studies, the main topic to be considered is the direct association 
between the sensitivity of the diagnostic test used and the percent-
age of oral-cervical infection detected. Kellokoski et al, in a study 
carried out over ten years ago on women with current and previous 
genital HPV infection, detected an elevated percentage of the virus 
present in normal oral mucosa in relation to the diagnostic protocol 
adopted: respectively through Dot Blot Hybridization (DBH) on 
cytologic samples the prevalence was 3.3%, by means of Southern 
Blot Hybridization (SBH) on histologic samples, prevalence was 
15.6% and lastly by means of PCR, on the same samples, there was 
23.1% prevalence [123]. Badaracco et al. [124] detected simultane-
ous oral-cervical infection in 5 of 29 patients (equal to 17.2%) by 
means of a molecular technique called “strip-test” which combines 
PCR with Reverse Blot Hybridization. Recently, Giraldo et al. de-
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tected, once again by means of PCR, the presence of the virus in the 
oral mucosa in over 37% of patients with both cytological and his-
tological lesions in the HPV-related genital area, a percentage 
which drastically drops to 4.3% in women without symptoms [125]. 
These results have led many authors to suggest that infection in the 
genital mucosa represents a condition which favours the progres-
sion of the viral infection of the oral mucosa, even if many studies 
have not found a genotypical concordance between the infection in 
the two areas. In Badaracco et al.’s study, in 3 of 5 cases of dual 
infection, HPV 16 was detected in both areas. In addition, some 
authors have highlighted, in a sample of women suffering from 
SCC of uterine cervix, a significant correlation of gt with cervical-
vaginal infection. In 23 of 28 women with concurrent HPV genital 
infection, they detected the same gt found in the oral area, leading 
to the hypothesis that the virus, after primary infection in the inocu-
lation site, is able to spread to other epithelial areas, i.e. the cervical 
mucosa, which is particularly susceptible to HPV infection and its 
oncogenic potential [126]. Smith et al [127] and Canadas et al. [33] 
instead, did not detect any genotypic oral-genital concordance in 
any of the patients examined. On the basis of this point and the fact 
that there is no corresponding infection in the partner, Smith et al. 
believed that both the possibility of infection through self-
inoculation or by sexual transmission was unlikely, and therefore 
put forward the hypothesis of a different susceptibility to HPV in-
fection in the two anatomic sites [127]. Canadas et al. were of the 
same opinion and assessed the many different areas where HPV 
infection may be present, (cervical, vaginal, vulvar, anal and oral 
mucosa) in a sample of high risk patients and they proposed a dif-
ferent affinity between the viral types compared in the two mucosal 
sites: in the anogenital area, infection caused by HPV HR was 
found in over 80% of cases, while in the oral cavity a predominance 
of HPV LR was detected [33]. The genotypic variability of the 
infection, which is commonly found even in monogamous partners, 
therefore, seems to depend on the differences relative to tissue 
characteristics and microbial flora of each mucosal site, even if 
other hypothesis must still be taken into consideration. In fact, some 
authors have linked the diverse anatomic susceptibility to different 
mechanisms of the immune system. In his study Goncalves et al. 
assumed that there was concordance between genital HPV infection 
and reduced concentration of IgA in saliva secretions, a condition 
which would explain the fall in the protective function of local anti-
bodies and therefore would make the oral cavity more susceptible 
to colonization by the virus [128]. Other authors put forward the 
hypothesis that dual or multiple infections may depend on a genetic 
predisposition which is probably connected in some way, as re-
cently suggested, to some HLA haplotypes, able to make the infec-
tion more susceptible individually and more likely to transform 
HPV-related lesions into malignant ones [129, 130]. In conclusion 
it is obviously necessary to carry out further research to clarify the 
frequency of the concomitant infection (oral and genital) in relation 
to possible risk factors and to social-behavioural variables, paying 
particular attention to sexual habits which lead to an increase in 
susceptibility to the infection. These studies presuppose a multidis-
ciplinary synergy involving diverse medical specializations (den-
tists, gynaecologists, virologists) to establish new ways of prevent-
ing HPV infection through effective diagnosis and treatment. 
4. THERAPIES FOR HPV INFECTION AND HPV-
RELATED LESIONS 
 For many infectious diseases, it is evident that therapy is bene-
ficial and that their eradication can be achieved by means of control 
and prevention of infection [131]. Conversely for HPV-related le-
sions, these considerations are not similarly correct. No current 
therapy is able to eradicate the HPV infection and the available 
therapeutic tools have a limited impact in preventing lesion recur-
rence and reducing the likelihood of viral transmission. Following 
the current therapies for HPV-related lesions in genital and oral 
mucosa are described (see Table 3). 
4.1. Management of Genital HPV Infection 
 None therapy is currently available and recommended for sub-
clinical genital HPV infection, since this condition is not definable 
as a disease and it is usually transitory and self-eliminating by the 
host immune system over 6-20 months (usually 8-10 months). It is 
imperative to carry out the follow up of the condition and the repe-
tition of HPV DNA test after this interval to verify the elimination 
of the infection, especially when sustained by HR HPV, potentially 
able to give a persistent and transforming infection [19, 37]. In 
addition adequate education and counselling of the infected patients 
is mandatory in order to control the horizontal transmission of in-
fection and/or autoinoculation at other epithelial sites of the body. 
Because HPV infection is highly contagious, current sexual partner 
of infected subjects are likely already HPV-infected. Condom use 
may reduce partially the risk of transmission because the virus is 
able to infect the epithelium of the entire anogenital tract. Routine 
clinical and virological examination of sexual partners is not man-
datory [132, 133]. On the other hand, female sex partners of male 
patients who have genital infection/warts should be reminded that 
cytological screening for cervical cancer is recommended; in fact 
among men, genital infection is more frequently unapparent than in 
women, where more frequently genital/cervical infection is associ-
ated with asymptomatic lesions [134]. 
 In presence of HPV-related lesions, the treatment is based on 
surgery, local or systemic administration of drugs (cytotoxic or 
immunomodulatory agents) or a combination of all of them [135] 
(Table 3). The decision whether to treat HPV-related lesions is 
strongly influenced by the clinical manifestations, symptoms and 
the potential malignancy. Genital warts and condylomas are associ-
ated with discomfort and physical/psychological dysfunctions; al-
though eradication of infection is not feasible, treatment of these 
benign lesions is warranted in order to reduce these negative as-
pects. However, before starting therapy, patients should be learned 
about the limitations of the current available therapy for genital 
warts/condylomas, because most of these are effective in clearing 
warts or temporary reducing their size, but recurrence rates are high 
after all treatments [131]. 
 Surgical, ablative and destructive therapy. Surgery remains the 
basic method for the treatment of the most frequent HPV-related 
anogenital lesions. The excision may be performed using cold 
knife, electrosurgery or laser after local anaesthesia. For anogenital 
warts and condylomas the standard therapy is the destruction of the 
lesion with cryosurgery, cryotherapy with liquid nitrogen, laser 
ablation (CO2) or electrocautery [135]. Other modalities of as-
pecific destruction of external benignant lesions are based on the 
typical application of acids (mono-, bi- and trichloroacetic acids – 
MCA, BCA, TCA respectively – and salicylic acid), or aldehydes 
(glutaraldehyde, formaldehyde). As for cryotherapy, the response 
rate range from 50-80% and about one-fourth of patients has a re-
lapse. The photodynamic therapy, based on the local application of 
photosensitizer agents (derived from porphyrins) selectively up-
taken by tumor cells, have been tested for HPV-related lesion, es-
pecially RRP, and successively for genital lesions (CIN, VuIN), 
with a response in about 50% of cases according Martin-Hirsch et 
al [136, 137]. Nevertheless, results of more recent studies were 
contrasting, also for RRP [138, 139]. 
 A specific treatment has been recommended for CIN, that is the 
application of the LLETZ (Large Loop Excision of Transformation 
Zone), derived from the Loop Electrode Excision procedure (LEEP) 
and associated with greater safety and efficacy (95% cure rate in a 
year) and minor recurrence rates than other surgical procedures 
[135, 140]. Other potentially malignant lesions of anogenital area 
(AIN, VaIN, VuIN, PIN) represent challenging clinical problems 
because there are no standard surgical recommendations as for CIN 
lesions [141]. Noteworthy, tobacco smoking represents a well 
known co-carcinogenic agent for development of these HPV-related 
diseases, so dedicated education and counselling for smoking cessa-
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tion in patients who smoke are required [19, 131]. A more detailed 
discussion of the treatment of anogenital intraepithelial neoplasia 
and SCC is not the aim of this review and we forward to dedicated 
gynaecological literature. 
 A significant proportion (about 50%) of patients treated in first 
line with surgery (especially with traditional cold knife technique or 
ablative therapy) are subjected to a recurrence and need of an adju-
vant medical treatment [142, 143]. Moreover ablative approaches 
Table 3. Management of HPV Infection/Diseases in Genital and Oral Mucosa 
 Genital mucosa Oral mucosa 
Strategy 
Treatment  
Dosage/ route of drug 
administration 
Reported clinical 
indication 
Treatment 
Dosage/ route of 
drug administration  
Reported clinical 
indication 
Surgery Cold knife 
Electro-surgery 
Laser therapy 
LLETZ 
 Warts 
Warts 
Warts 
CIN 
Cold knife 
QMR scalpel  
 
 
 
Electro-surgery 
Laser therapy 
 Benignant lesions 
HPV-related lesions 
and OPMD (if ab-
sent/low grade dyspla-
sia ) 
 
Not recommended 
Not recommended  
Ablative destruc-
tive therapy 
Cryotherapy 
MCA, BCA, TCA 
 
Aldehydes 
Salicylic acid  
Photodynamic therapy 
 
Topical 80-90% solu-
tion (office use) 
 
 
 
External warts 
External warts 
 
External warts 
External warts 
CIN, VuIN 
Photodynamic 
therapy 
 
 
 
 
 
 Limited clinical data 
(OL, PVL) 
 
Other ablative therapies 
are not tested for oral 
mucosal use 
Antiproliferant, 
citotoxic and anti-
viral agents 
Podophyllin 
 
 
Podophylloxotin 
 
 
 
5-FU 
 
 
 
Cidofovir 
Topical 10-25% solu-
tion  weekly (office 
use) 
 
Topical 0.5% solution 
twice/day for 3 days 
(self-application) 
 
Topical 5% cream 1-3 
times/week (self-
application) 
 
Topical /intralesio-nal 
injection 
Warts 
 
 
Warts 
 
 
 
Warts 
 
 
 
Warts and CIN 
  
Drugs scarcely/not 
tested for oral mucosal 
use. 
Not specific regimes 
and dosage are cur-
rently available.  
Immunomodulator 
agents 
IFN  and  
 
 
 
Imiquimod 
Topical/intralesional 
injection/systemic  
 
 
Topical 5% cream 3 
times/week 
Warts (limited indi-
cation) 
 
 
 
Warts 
  
Drugs scarcely/not 
tested for oral mucosal 
use. 
Not specific regimes 
and dosage are cur-
rently available. 
Novel therapies Ribozymes 
siRNA 
Antisense oligonu-
cleotides 
Molecular E6/E7 
targeted therapy 
 
Limited clinical data 
out of standard 
therapy 
  
No data are available 
for oral mucosa 
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have significant sequelae such as bleeding, scarring, pain and in-
flammation. In addition, when visible lesions are effectively re-
moved, residual viral particles or DNA in surrounding tissues may 
reseed the treated site and lead to recurrence of lesion. A series of 
medical therapies have been proposed, as following reported. 
 Antiproliferative, cytotoxic and antiviral agents. These drugs 
play as metabolic inhibitors when topically applied or injected into 
visible lesions. Podophyllin, resin extracted from the roots of some 
Berberiacee species, are a cytotoxic agents able to arrest mitosis at 
metaphase by binding tubulin and also to destroy HPV virions. It 
was abandoned in favour of its derived podophyllotoxin (also 
known as podofilox), associated with minor local and systemic side 
effects, indicated for topical treatment of external genital warts 
(0.5% solution) [144] (Table 3). 5-Flururoacil (5-FU) inhibit DNA 
and RNA synthesis and acts as antimetabolite when used topically 
as 5% cream for self-application for treatment of multifocal and 
extensive genital warts or VaIN/ VuIN, although its use is recently 
restricted because frequently cause local irritation [144]. Bleomy-
cin, able to bind DNA, is not indicated for mucosal lesions because 
intralesional injection is very painful and associated with local side 
effects (swelling and eschar formation) [145]. Cidofovir is a nu-
cleotide analogue (acylic nucleoside phosphonate) able to inhibit 
DNA synthesis and, according some reports, may induce apoptosis 
[146]. It has a broad spectrum antiviral activity against several 
DNA viruses. However, the rational for using cidofovir for the 
treatment of HPV-related lesions is not clear since the HPV replica-
tive cycle is completely different from other DNA viruses sensitive 
to this molecule, so the question remains if the activity of cidofovir 
against HPV produces more antiproliferative than antiviral effects. 
Its clinical use as topical cream or injected solution, intralesionally 
or systemically, has been tested in several HPV-related lesions 
(anogenital condylomas, skin warts, CIN, recurrent respiratory 
papillomatosis) with success [147], also among immunocom-
promised patients [148] and as co-adjuvant agents to ablative and/or 
surgical removal to reduce relapse [149]. However large random-
ized clinical trials are still not available, thus different questions 
(about the exact mechanism of action, the treatment modalities, the 
response rate and the suspected carcinogenic potential of the mole-
cule) still remain [150].  
 Immunomodulatory drugs. While previous strategies act indis-
criminately destroying both healthy and infected tissues, approach 
with immunomodulatory agents consent to enhance the host im-
mune response in order to organize a selective defence to HPV 
infected cells. This effect may be obtained directly by local applica-
tion of interferon (IFN), or, indirectly, by administration of imiqui-
mod. IFN  and , playing both immunomodulatory and direct an-
tiviral activity, were used alone or in association with other drugs 
for treatment of several HPV-related lesions, especially when diffi-
cult to treat with surgery, such as RRP [141]. IFN may be used with 
several routes of administration (topical application, intralesional 
injection, systemic), but the variable efficacy results with frequent 
rebound phenomenon at the end of therapy [151], the high costs and 
the frequent systemic side effects (i.e. leukopenia, fever, head-
heache, myalgia, asthenia), have progressively limited the use of 
these molecules [144]. Imiquimod, a member of the class of imi-
dazquinolines, acts as a potent immunostimulator, antiviral and 
antitumoral agents in animal model. Imiquimod demonstrated able 
to induce the release of pro-inflammatory Th1 class cytokines from 
lymphocytes and macrophages (e.g. IFN-, - and –, TNF and 
IL12) and to enhance cell-mediated local immunity against viral 
targets, mechanisms that may facilitate viral clearance. It has been 
indicated topically (5% cream) for the treatment of genital warts 
[131, 152, 153] recently, some case series test its efficacy in pa-
tients with VuIN [154], AIN [155], carcinoma in situ of the penis 
[156]. Imiquimod is well tolerated, only mild to moderate local side 
effects (inflammation) have been reported, but the not conclusive 
results of reported small sized studies and lack of large series and/or 
RCT and have reduced the use of this agent. 
 Very recently Roberts et al. [157] reported interesting findings 
about the topical use of carrageenan to reduce susceptibility to HPV 
of cervical mucosa during cytology screening. The same molecule 
have been proposed as adjuvant to peptide-based vaccine for their 
ability to induce antigen specific immune response, especially 
against E7 [158]. 
 Noteworthy, an important limitation of the immune-modulatory 
therapy is that the viral replicative cycle and the protein transcrip-
tion in the infected cells entirely occur into the nucleus and the 
cytoplasm, without expression of viral protein on the cellular mem-
brane, in this way infection happens without immune response acti-
vation. Moreover the viral oncoproteins E6 and E7 have specific 
mechanisms for abrogate the host immune response [159]. These 
two mechanisms may explain the variable efficacy of immune-
therapies in different patients in presence of specific HPV geno-
types. 
 New therapeutic strategies. The new therapeutic challenge is 
the development of more targeted strategies based on nucleic acids 
(small interfering RNA, antisense oligonucleotides, and ribozymes 
able to inhibit expression or activity of viral proteins) [159, 160]. 
E6 and E7 proteins demonstrated to play together to nullify host 
immune responses, thus interdicting E6- and E7- mediated actions 
could increase the likelihood of infection elimination by the natural 
immunity. 
 For E6 targeting therapy, the abrogation of telomerase activity 
and the interdiction of E6-p300/CBP interaction have been studied 
[159, 161-164]. 
 For E7 targeting strategy, potentially candidate for therapeutic 
intervention is the interaction of E7 proteins with cdk inhibitors 
(CKIs: p21CIP1 and p27
KIP1
)
 
and the disruption of the E7-IRF-1 
complex and/or inhibition of HDAC activity [159, 165, 166]. 
 In addition numerous other interaction between HPV E/L pro-
teins and host regulatory factors have been recognized are still stud-
ied for molecular targeted strategy (reviewed in [159, 167]), never-
theless the use of this approach is still a promising strategy that will 
require further exploration.  
4.2. Management of Oral HPV Infection 
 As discussed with respect to genital HPV infection, also in oral 
cavity HPV subclinical infection does not need of treatment since 
any tested antiviral drugs (e.g. acyclovir, ribavirin) have been dem-
onstrated able to eliminate the infection [135] (Table 3). The man-
agement of this condition is based on the follow up of the patient 
over at least 8-12 months, repetition of HPV DNA test after this 
interval and periodically until elimination of the infection occurs. 
As assumed for gynaecology field, a persistent viral status (sus-
tained by HR-HPV types) maintained for at least 2 years represents 
a necessary although not sufficient basis for HPV-related lesions 
[46, 47, 85, 168]. Differently by gynaecologists, employing a stan-
dard sampling method for HPV testing in uterine cervix, in oral 
medicine a uniform method of specimens collection for HPV detec-
tion still does not exist. Several procedures of oral specimens col-
lection were evaluated in literature [169, 170]. However, the virus 
is rarely found in oral mucosa, probably due to saliva clearance. 
Potentially, it is more probable that tonsillar crypts and the glot-
tides, more susceptible to viral entry and replication [171], will 
constantly harbour virions than other mucosal oral districts, and 
they will be detected with greater difficultly. Furthermore, in most 
studies, the exact anatomic sites of the samples are not given and 
thus, the origin of HPV infection (whether oral or oropharyngeal) is 
impossible to trace.  
 The samples are taken either as mucosal scrapings, oral rinses 
or tissue biopsies. The biopsy remains one of the most common 
procedures of oral sampling, thanks to the possibility of using the 
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same specimen for morphological examination as well as for the 
HPV test, also in different timing. The biopsy, moreover, provides a 
more representative sample of oral mucosa as compared with exfo-
liative cytology and includes cells from the basal layer, where the 
virus could be present in a latent form. On the other hand, the exfo-
liative cytology is less invasive than a biopsy, especially in absence 
of lesions, allows to harvest cells from a greater surface area and 
involve minor chance of contamination before DNA extraction than 
a surgical procedure [76, 172, 173]. When a scraping is taken from 
an keratinized mucosa (similar as the skin) (e.g. hard palate, gum), 
the sample is frequently inadequate due to the low number of nu-
cleated cells. Overall, the HPV detection rate is higher in oral rinse 
samples (12-51%) and oral scrapings (45%) than in brush samples 
from the tonsils (3%) or biopsies (12%) [31, 174-176].  
 Lately, the oral rinse was proposed as method of cytological 
sampling more efficient than the superficial brushing/scraping of 
oral mucosa in terms of DNA yield, quality and stability, as well as 
acceptability by the sample donor [177, 178]. In oral rinse, how-
ever, the majority of HPV-positive cells might origin from the oro-
pharynx and tonsils. A recent meta-analysis on oral and oropharyn-
geal cancers showed that a representative biopsy from the lesion 
resulted in the highest HPV detection rates especially when PCR 
was used (29.8% versus 38.1%) [179]. Not only the sampling itself, 
but also the technical aspects in sample processing are of impor-
tance e.g. the sample transport media, storage time and -
temperature. For example in saliva, there are some 10 million bac-
teria/ml which might compromise HPV testing. The media used for 
HPV testing of oral scrapings include the same transport media as 
used also for cervical samples (usually slightly alkaline buffers with 
antibiotics), ethanol [23-25, 180, 181] or mouth wash [182]. 
 The sensitivity and specificity of the HPV testing method as 
well as the expertise of the researchers in interpreting the results are 
of key importance in addition to sampling site and sample process-
ing. In a previous study, it has been found that 3 sequential swabs 
from the buccal mucosa will result in approx. 100.000 cells which 
is optimal for HPV testing [175]. In these samples, HPV detection 
rate was related to the sensitivity of the HPV testing method; HPV 
DNA was found in 3.8%, 15.6% and 23.1% with dot blot hybridiza-
tion, Southern blot hybridization and PCR, respectively [31, 175]. 
An important aspect frequently neglected is the quality of DNA for 
PCR, particularly because the microbe load is so high in saliva. A 
purified DNA will result in much higher HPV detection rate than 
non-purified DNA, as shown by us already in 1997 [180, 181], and 
confirmed by D’Souza and co-workers in 2005 [182]. Nested PCR 
will increase HPV detection rate and should be used especially 
when the cell count in the sample is not optimal. In our Finnish 
Family HPV Study, we have used nested PCR with subsequent 
hybridization. With this method, we found high-risk HPVs in 16% 
to 27% of the oral scrapings taken in 80% ethanol. DNA extraction 
was made with the high salt method [23-25]. Similarly, Kay et al 
2002 reported that HPV detection rate in buccal swabs increased 
from 19% to 74% when single PCR with MY09/11 primers was 
replaced by nested PCR with MY09/11 and GP05+/06+ primers 
[183]. 
 Very important are also the counselling about tobacco smok-
ing/alcohol drinking cessation and education about hygiene and 
sexual practices (in terms of dishes sharing and direct contact with 
other individuals). About association with common risk factors, has 
been described that alcohol abuse increases the risk of HPV infec-
tion, especially among OSCC patients [184, 185]. 
 Smith et al. [177] demonstrated that alcohol had an independent 
and synergistic effect with HPV increasing the risk of viral persis-
tence and cancer development. It is biologically plausible that an 
interaction effect between HPV and alcohol may occur: alcohol 
could biologically modify mucosal tissue, potentially increasing its 
permeability to viral infection, or it could influence the immune 
response to HPV [186]. Although some studies have reported con-
trasting results about the association between HPV infection and 
alcohol [6, 43, 187, 188] and it deserves to be better investigated, 
advocating patients in alcohol abuse cessation is recommended. The 
same recommendation are true for tobacco smoking; although not 
uniform results was reported until now, the recent large study of 
Sanders et al reported a prevalence of HPV infection in current 
smokers more than twice that of non-smokers (12.7% vs. 5.1%), 
with a dose-related response confirmed also by serum cotinine con-
centration [6]. Noteworthy is also the elimination of any trauma 
(fractured teeth, restorations with cutting margins, incongruous 
prostheses), since a previous study reported an unexpected high 
frequency (about 26%) of HPV DNA detection in benignant oral 
erosive-ulcerative lesions (EULs) of probably traumatic origin [43]. 
HPV infection could be due to the oral lesion per se, similarly to 
findings in the genital mucosa, where mechanical trauma can lead 
to epithelial basal cell exposure and subsequent HPV entry and 
replication. This preliminary datum, if substantiated by studies with 
larger numbers of patients, could have both screening and etiologic 
implications since long-term follow-up of patients with a history of 
HPV-positive EULs could be helpful in evaluating any clinically 
different behaviour (tendency to persistence or recurrence or likeli-
hood of progression to premalignant stages), compared with HPV-
negative EULs. 
 Regarding the hygienic and sexual practices, sexual behavior is 
strongly indicative of HPV infective status also in oral cavity, in 
terms of early sexual debut and multiple sexual partners. Odds for 
HPV detection were found by Sanders et al in U.S. population 
about 10 times greater among individuals reporting 20 or more 
lifetime sexual partners compared to these with less than 3 partners. 
Because divorced/separated individuals had greater OR of HPV 
infection than married, the authors have postulated that single status 
is indicative of higher number of sexual partners. The possibility of 
auto-infection among women with cervical HPV infection is still a 
matter of debate [189, 190]. In a recent metanalysis, prevalence of 
concurrent oral and genital HPV infection among women was esti-
mated to be 18.1%, with a type-specific concordance in 27% of 
bifocal infection (p=0.002), and this evidence was found more 
strong among HIV infected women [189]. Furthermore, oral sex, 
including fellatio and cunnilingus, has being hypothesized as the 
main way of transmission for oral HPV infection. Recently, HPV 
was detected more commonly in biopsy specimens from cancer 
patients with more than one sexual partner and from those who 
practiced oral sex than in biopsy specimens from those who did not 
engage in oral sex, thereby confirming the possibility of oral trans-
mission [191]. However, mouth-to-mouth transmission, for exam-
ple through kissing, still remains possible and it should not be ex-
cluded as a route of oral HPV transmission. Since the onset of the 
HIV epidemic, an increase in oral sex among teenagers and young 
adults has been observed, probably because this is thought to repre-
sent a form of safe sex. However, oral sex is not risk free and it can 
result in HPV-related HNSCC. According to recent epidemiological 
data, a different segment of population in now at risk of HNSCC, 
especially OPSCC, i.e. young Caucasian males [9, 192] have esti-
mated that if the current incidence trend will continues, the annual 
number of HPV-positive OPSCC might exceed the annual number 
of CSCC by 2020. Public education is of paramount importance: 
there is a need to disseminate these findings and to place them in 
context. 
 If a given HPV-related lesions is present, the treatment is based 
mainly on surgery, since local or systemic applications of medica-
tions (cytotoxic or immunomodulatory drugs) were extensively 
tested in head and neck district only for RRP, as above reported, 
and not for oral mucosal lesions. Recently, an experimental study 
has tested a bio-adhesive patch system releasing imiquimod for the 
topical treatment of dysplastic and neoplastic lesions (dose-
controlled topical delivery) that may allow to extend the clinical 
uses of this immunomodulatory agent to the treatment of potentially 
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malignant lesions conditions of oral as well genital mucosa recog-
nized to be HPV- infected [193]. 
 Surgical therapy. The excision of the lesions, associated with 
HPV DNA test (usually performed in epithelial cells collected by 
oral rinse/brushing before surgery or in formalin-fixed/paraffin-
embedded or fresh frozen histological samples) could be carried out 
after local anaesthesia by traditional cold knife, quantic molecular 
resonance (QMR) scalpel [194] or electro-surgery. The last tech-
nique could influence negatively the histological examination, es-
pecially in presence of small sized lesions, because of cauterization 
of margins of the samples. Likewise, since the laser ablation of 
HPV-related lesions is to discourage, since the histological diagno-
sis is essential to distinguish each HPV-related lesion from the oth-
ers HPV-unrelated with similar clinical presentation and to identify 
any grade of epithelial dysplasia, if present.  
 In presence of lesions sized more than 2 cm or multifocal, espe-
cially if a PMD or carcinoma in situ/OSCC is suspected, an inci-
sional single or multiple biopsy is recommended, eventually pre-
ceded by mapping with a vital colorant (Toluidine blue) or a visual 
device (e.g. VelScope®, Sapphire®). The complete excision of the 
lesion should be postponed after histological diagnosis and diversi-
fied on the basis of the presence and degree of dysplasia or carci-
noma. However, the patients should be informed that, in light of the 
multifocal nature of oral and oropharyngeal infection, surgical re-
moval of the lesion does not guarantee elimination of infection, 
because viral DNA could persist in normal adjacent mucosa [174]. 
New Perspectives for Management of OPMDs/OSCC/OPSCC and 
HPV Infection 
 About prognosis of HPV-infected OPMDs and carcinoma, 
some questions still raise: while it is very doubtful if HPV could 
influence the malignant progression of OPMDs [12, 195], with 
respect to OPSCC and OSCC, recent clinical data in the literature 
confirm that HPV infection represents the most significant positive 
prognostic factor. Furthermore, HPV 16 has been positively associ-
ated with a better response to chemo-radiation in OPSCC. The 
HPV-related OPSCC “epidemy” may give a possible explanation 
for the overall and disease-specific survival rates for SCC of tonsils 
and base on tongue, regardless of stage at diagnosis and type of 
therapy [196-199]. This evidence may have important clinical and 
therapeutic consequences, since the routinely detection of p16 as a 
surrogate marker or HPV DNA directly should be performed and 
considered as a key factor in the decision-making process of treat-
ment [200, 201]. However, we are unable to make the same sugges-
tion for the OSCC. Currently a case-control observational case-
control perspective study is in progress entitled “Biomarkers of 
immune function as predictors of head and neck squamous cell 
carcinoma (HNSCC) in response to therapy” (registered on Clini-
calTrials.gov Archive Site, identifier code NCT01358097), by the 
recruitment of LSCC/OPSCC positive and negative for HPV versus 
normal healthy volunteers. The purpose of that study is to investi-
gate the role of the immune system in the response of HNSCC to 
treatment with respect of HPV infection. The investigators are test-
ing the hypothesis that radiation-based therapy of OPSCC is associ-
ated with activation of the endogenous HPV-specific immune re-
sponse. The results could provide valuable information to better 
understand the body's interaction with cancer cells and could sug-
gest novel therapeutic approaches for HPV positive HNSCC. 
Noteworthy, during the last 2011 ASCO annual meeting (American 
Society of Clinical Oncology), several researchers have reported the 
different outcomes and response to therapy of OPSCCs HPV-
positive vs. HPV-negative ones [202-204]. They have found inde-
pendently a better survival and low locoregional failure rates fol-
lowing any modalities of treatments, including novel approaches as 
nonsurgical definitive radiotherapy (IMRT) and mini-invasive sur-
gical approaches as TLM (transoral laser microsurgery) followed 
by post-operative chemo-radiotherapy. These results were obtained 
regardless the higher stages and the higher frequency of nodal me-
tastases of HPV-positive than HPV-negative OPSCCs and further 
strengthen the option to consider HPV-status when planning pro-
spective studies on treatment for base of tongue and tonsillar SCCs. 
 New therapeutic perspectives regard the opportunity to use 
HPV vaccines for targeted therapy of HPV-positive HNSCC can-
cer, especially OPSCC. Several researchers worldwide are still 
studying this challenging field: a clinical trial is in progress in UK 
at LTCU (Liverpool Cancer Trials Unit), named REALISTIC, on 
the efficacy and safety of a Recombinant Listeria Monocytogenes 
(Lm)-based vaccine encoding Human Papillomavirus Target Anti-
gens (i.e.ADXS11-001) in patients With HPV-16-positive OPSCC. 
If proved safe, ADXS11-001 may be introduced as a post-treatment 
adjuvant as part of a treatment de-escalation strategy in an attempt 
to reduce the adverse effects of current treatment strategies without 
compromising survival (from web site http: //www.lctu.org.uk/ 
trial/trial_info.asp?id=73&tgcode=2&menuid=30). Another not 
randomized clinical trial is currently under way at Maryland Uni-
versity, with the aim to test a vaccines comprised on the Trojan 
peptides MAGE-A3 and HPV 16 for treating patients with HNSCC 
who have recurrent, progressive or metastatic tumours (study regis-
tered on ClinicalTrials.gov Archive Site, identifier number 
NCT00257738). Findings of this phase I open labels and, preferably 
of randomized clinical trials not yet performed, could contribute in 
the next future to the implementation of HPV-related HNSCC ther-
apy, especially for base of tongue and tonsils SCC, in order to as-
sure better prognosis, a surgery as conservative as possible and 
improved quality of life. On the basis of the lower evidence of a 
causative role of HPV in the development of other not site-specific 
OSCC, it is not possible forwarding these preliminary data to SCC 
located in oral cavity. 
5. PREVENTION OF HPV INFECTION: VACCINES 
 To date, three preventive HPV vaccines have been developed 
and clinically evaluated in randomized clinical trials [205]:  
i. monovalent HPV 16 vaccine (manufactured by Merck, Sharpe 
& Dome, Whitehouse Station, NJ, USA);  
ii. quadrivalent vaccine containing L1 protein of HPV 6, 11, 16 
and 18 (Gardasil®, produced by the same manufacturer);  
iii. bivalent vaccine containing L1 of HPV 16 and 18 (Cervarix®, 
produced by GlaxoSmith, Rixensart, Belgium). 
 The first vaccine has not been commercialized, while Gardasil® 
and Cervarix® were licensed by FDA (Food and Drug Administra-
tion) in U.S. in 2006 and 2009, respectively. 
 The quadrivalent vaccine was first licensed for use in females 
aged 9-26 years for prevention of cervical, vaginal and vulvar SCC 
and precursors (CIN, VaIN, VuIN) [206, 207]. Three years later, its 
use was extended to males in the same range of age because it was 
tested in males, being demonstrated effective against penile SCC 
[208], and lately FDA further enlarged the indication to prevention 
of AIN and anal SCC [206, 209]. Moreover the quadrivalent vac-
cine is approved for prophylaxis of genital warts/condylomas due to 
HPV low risk types 6 and 11. In clinical trials, Gardasil® has dem-
onstrated very high effective for prevention of all types of anogeni-
tal cancer precursors, either among naive-individuals (efficacy 
>98%) and HPV 6-11-16-18 infected patients (efficacy ranging 
from 50-78%) [210, 211]. 
 The bivalent vaccine has been tested only for cervical SCC and 
precursors, not for other HPV-related malignancies/pre-
malignancies, and licensed for use in girls aged 10-26 years [212]. 
Like previous vaccine, Cervarix® has a very high efficacy in pre-
venting HPV 16 and 18-related CINs and CSCCs, especially in 
naive subjects) among naive HPV16 and 18 subjects (>97%) [211]. 
Nevertheless, based on the structural similarities between quadriva-
lent and bivalent vaccines, it is reasonable believing that also Cer-
varix® will also be effective for HPV 16 and 18 related lesions in 
other anatomical sites.  
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 Both HPV vaccines need of three doses, the first at day 1, the 
second at month 1 for bivalent vaccine and month 2 for quadriva-
lent one, and the third at month 6 [213]. 
 To date the vaccines are available in most European countries 
and in over 70 states worldwide; several developed countries have 
approved, after U.S., national HPV vaccination programs based on 
administration mainly of quadrivalent vaccine to 9-17 years old 
girls (i.e. Sweden, Italy, France, Netherland, Germany, Switzerland, 
Denmark, Spain, Belgium and other ones), with an overall accep-
tance rate of about 50% [153, 214]. Program advantages are di-
rected both to individuals receiving directly the vaccine (adolescent 
girls) and those who benefit from the so called herd immunity 
(when vaccinated susceptible individuals benefit from reduced HPV 
transmission induced by vaccination of other subjects, at least for 
HPV types covered by vaccines). It is noteworthy that, at popula-
tion levels, to obtain successful herd immunity, vaccination should 
cover 80% of the population. In this context, vaccination programs 
including boys in addition to girls may be justified to pursuit this 
ambitious goals [215], although, the expensive cost could limit this 
approach in less developed or developing countries. Other crucial 
questions still raise: assessing the age of the first contact with the 
virus in order to give HPV vaccines to naive individuals and guar-
antee the greatest efficacy and the opportunity to extend the vacci-
nation to homosexual males, to date not protected indirectly from 
reduced heterosexual transmission deriving for adolescent girls 
vaccination programs. The greater benefits obtainable through vac-
cination of this category of patients are more evident bearing in 
mind that they also frequently acquired HIV infection and so they 
are at high risk to HPV-related diseases, especially AIN and anal 
SCC. 
 While no direct evidence exists about the efficacy of the vac-
cines in reducing the acquisition and the expression of HR HPV in 
the oral cavity and oropharynx, once these vaccines are effective in 
anogenital region, it seems reasonable to believe that they may play 
against the same HPV types in other mucosal sites as well [6, 206]. 
If proven to do so, these vaccines would represent a major break-
through in preventing all HPV-related diseases, including OPSCC, 
and also providing the definitive evidence that HPV is the cause of 
these tumours. The impact of HPV vaccination programs on future 
cancer incidence will take decades, and the use of national cancer 
registries is essential to evaluate the outcomes on the epidemiology 
of HPV-related diseases (i.e. incidence rates of cervical, anogenital 
and oral/oropharyngeal SCCs and their precursors; incidence of 
benignant HPV-related lesions in all sites and, finally, vaccine 
safety) [216]. 
6. CONCLUSIONS 
 The last decades have produced very relevant growing of 
knowledge about the molecular steps in the life cycle of HPV, the 
biochemical properties of viral oncoproteins and remarkable pro-
gresses have been made about the diagnostic methods of HPV DNA 
detection. Understanding the interplay between HPV and host cell 
pathways provide many potential new targets for disrupting the 
viral infection process and for the development of novel viral spe-
cific therapies for HPV infection in oral cavity. To date, the best 
therapeutic management of oral HPV-related diseases, both benig-
nant and potential malignant ones, is the surgery. Medical therapy, 
as topical and systemic drugs, has been tested for treatment of the 
most common genital lesions and of RRP, but not also for oral mu-
cosal diseases. Furthermore, adequate campaigns of primary pre-
vention (sexual education, vaccination programs) could lead to the 
control of the infection in oral and oropharyngeal tract similarly to 
genital districts. All these perspectives represent big challenges that 
will require several years as well as would hesitate in eradication of 
HPV-related malignant diseases.  
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